RELB Antibody, HRP conjugated

Size

100ug

Clone Number

Aliases

I REL antibody; I-Rel antibody; IREL antibody; Nuclear factor of kappa light polypeptide gene enhancer in B cells 3 antibody; relB antibody; RELB_HUMAN antibody; Reticuloendotheliosis viral oncogene homolog B antibody; Transcription factor Rel B antibody; Transcription factor RelB antibody; v rel avian reticuloendotheliosis viral oncogene homolog B antibody; v rel reticuloendotheliosis viral oncogene homolog B antibody

Immunogen Species

Homo sapiens (Human)

UniProt ID

Q01201

Immunogen

Recombinant Human Transcription factor RelB protein (400-579AA)

Raised in

Rabbit

Species Reactivity

Human

Tested Applications

ELISA

Background

NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49. As a member of the NUPR1/RELB/IER3 survival pathway, may provide pancreatic ductal adenocarcinoma with remarkable resistance to cell stress, such as starvation or gemcitabine treatment. Regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-ARNTL/BMAL1 heterodimer in a CRY1/CRY2 independent manner. Increased repression of the heterodimer is seen in the presence of NFKB2/p52.

Clonality

Polyclonal

Isotype

IgG

Purification Method

>95%, Protein G purified

Conjugate

HRP

Buffer

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4

Form

Liquid

Stroage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Target Names

RELB

Research Areas

Epigenetics and Nuclear Signaling; Cancer; Cell biology; Signal transduction